21 October 2016

PJSC Pharmstandard (the "Company") - Intended delisting of global depositary receipts ("GDRs") from the standard listing segment of the Official List (the "Official List") of the Financial Conduct Authority, cancellation of trading of the GDRs on the Main Market of the London Stock Exchange plc (the "London Stock Exchange") and intended termination of the deposit agreement in respect of the GDRs dated 30 April 2007 between the Company and The Bank of New York Mellon (the "Depositary") (the "GDR Deposit Agreement")

The Company announces that at a meeting of its Board of Directors (the "Board") held today the Board has resolved to proceed with the cancellation of its London GDR listing and, in due course, to proceed with the termination of its GDR Deposit Agreement.

Following such decision of the Board, the Company announces today of its intention for the GDRs representing interests in the Company's ordinary shares to be removed from the Official List of the Financial Conduct Authority and the trading of the GDRs on the Main Market of the London Stock Exchange to be cancelled.

As previously announced, Augment Investment Limited ("Augment"), the controlling shareholder of the Company, completed a cash tender offer by which it acquired 17,461,550 GDRs from remaining GDR holders and subsequently completed a mandatory cash tender offer by which it acquired 4,538,675 ordinary shares of the Company from remaining shareholders resulting in Augment, together with its affiliate OJSC "Pharmstandard-Leksredsvta", holding 98.117 per cent of the Company's issued share capital as at 27 September 2016. The Company has also previously announced that, taking into account the outcome of the tender offers and the possible squeeze-out of remaining shareholders of the Company by Augment, the Company amended its GDR Deposit Agreement to remove the Company's obligation to use reasonable efforts to obtain and maintain a quotation for, or listing of, the GDRs on any of the EEA Regulated Markets and the Depositary has agreed to waive the cancellation fee, the 2016 depositary service fee, and any other fees payable by GDR holders under the GDR Deposit Agreement, provided that the Company serves a notice confirming its intention to terminate the Company's GDR program by November 21, 2016. Consequently, and in accordance with Augment's previously stated intention that it will seek to procure cancellation of the Company's GDR listing in London, the Company is now seeking cancellation of its London GDR listing.

An application has been made to the Financial Conduct Authority for the GDRs to be removed from the Official List of the Financial Conduct Authority and to the London Stock Exchange for trading in the GDRs to be cancelled with effect from 29 November 2016.

The last day of dealings in the GDRs on the London Stock Exchange is expected to be 28 November 2016.

The cancellation of the listing and of trading in the GDRs on the London Stock Exchange is expected to take effect at or about 8:00 a.m. on 29 November 2016.

The Company is intending to serve notice on the Depositary to terminate the GDR Deposit Agreement in the near future and intends to make a further announcement in this regard.

For further information please contact

Alexey Chernushkin

PJSC Pharmstandard

Likhachevsky Drive, 5 b, Dolgoprudny, Moscow, 141701, Russian Federation

Tel: +7 (495) 970-0030

Email: ir@pharmstd.ru

_____________________________________________________________________________________

***

FORWARD-LOOKING STATEMENTS

THIS RELEASE MAY INCLUDE STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE, "FORWARD-LOOKING STATEMENTS". THESE FORWARD-LOOKING STATEMENTS SPEAK ONLY AS AT THE DATE OF THIS RELEASE. THESE FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE WORDS "TARGETS", "BELIEVES", "EXPECTS", "AIMS", "INTENDS", "WILL", "MAY", "ANTICIPATES", "WOULD", "COULD" OR "SHOULD" OR SIMILAR EXPRESSIONS OR, IN EACH CASE THEIR NEGATIVE OR OTHER VARIATIONS OR BY DISCUSSION OF STRATEGIES, PLANS, OBJECTIVES, GOALS, FUTURE EVENTS OR INTENTIONS. THESE FORWARD-LOOKING STATEMENTS ALL INCLUDE MATTERS THAT ARE NOT HISTORICAL FACTS. BY THEIR NATURE, SUCH FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER IMPORTANT FACTORS BEYOND THE COMPANY'S CONTROL THAT COULD CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE BASED ON NUMEROUS ASSUMPTIONS REGARDING THE COMPANY'S PRESENT AND FUTURE BUSINESS STRATEGIES AND THE ENVIRONMENT IN WHICH THE COMPANY WILL OPERATE IN THE FUTURE. FORWARD-LOOKING STATEMENTS ARE NOT GUARANTEES OF FUTURE PERFORMANCE. THERE ARE MANY FACTORS THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS TO DIFFER MATERIALLY FROM THOSE EXPRESSED IN SUCH FORWARD-LOOKING STATEMENTS. THE COMPANY EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING TO DISSEMINATE ANY UPDATES OR REVISIONS TO ANY FORWARD-LOOKING STATEMENTS CONTAINED HEREIN TO REFLECT ANY CHANGE IN THE COMPANY'S EXPECTATIONS WITH REGARD THERETO OR ANY CHANGE IN EVENTS, CONDITIONS OR CIRCUMSTANCES ON WHICH ANY SUCH STATEMENTS ARE BASED.